A new Form 4 filing shows Forbion Growth Opportunities Fund III Cooperatief U.A., listed as an insider of Braveheart Bio, Inc. (BRVE), purchased 1,920,000 shares of the company on August 7, 2026. The shares were bought on the open market at $18.00 apiece, for a total outlay of $34,560,000.00. Following the purchase, the fund’s directly held stake stands at 11,640,546 shares.
This was not an isolated trade. Regulatory filings show two open-market purchases occurred between August 7, 2026 and August 7, 2026, together totaling $64,800,000.00. The size and concentration of this buying activity is why whoisbuyingnow.com is classifying the signal as a cluster buy — a pattern where multiple insider purchases land in a tight window, often drawing more attention from market watchers than a single transaction would on its own.
What the Filing Shows
Open-market purchases like this one require the insider to spend their own capital to acquire shares directly from the market, as opposed to receiving stock through options, grants, or other compensation-related mechanisms. That distinction matters to analysts who track insider activity, since it reflects a deliberate decision to allocate capital toward the company’s stock at prevailing market prices rather than through a pre-set compensation structure.
Forbion Growth Opportunities Fund III Cooperatief U.A. is identified in the filing simply as an insider of Braveheart Bio, without further detail on committee membership or officer title disclosed in this particular filing. The fund’s post-transaction ownership of 11,640,546 shares, held directly, indicates a substantial existing position in the company even before this latest purchase.
Why Clustered Buying Draws Attention
Academic research on insider trading disclosures has found that clustered purchases — multiple insiders or related entities buying within a short window — have historically shown a statistical correlation with subsequent stock outperformance, more so than isolated single purchases. That said, this correlation is a general pattern observed across large datasets of historical filings, not a predictive signal tied to this specific company or transaction, and it should not be read as guidance on what to do with BRVE shares.
The $64.8 million total spent across these two purchases represents a significant capital commitment disclosed publicly through SEC filings. Readers interested in the underlying documentation can consult the original Form 4 filing for the complete transaction record.
→ See all BRVE coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.